Eli Lilly

Eli Lilly and Company (NYSE: LLY) is one of the world's largest pharmaceutical companies, known for developing and manufacturing a wide range of prescription medications for humans and animals.

Founded in 1876 in Indianapolis, Indiana, Eli Lilly has grown into a global biopharmaceutical leader with over 42,900 employees worldwide as of 2023. The company focuses on key therapeutic areas including diabetes, oncology, immunology, and neuroscience. Some of Lilly's top-selling products include Trulicity and Mounjaro for diabetes, Verzenio for breast cancer, and Taltz for psoriasis.

Eli Lilly operates through several business segments, including human pharmaceutical products and animal health. The company invests heavily in research and development, spending over USD 5 billion annually to advance its pipeline of potential new medicines. Lilly has manufacturing facilities in multiple countries and sells its products in approximately 120 nations globally.

In recent years, Eli Lilly has seen tremendous growth driven by its diabetes and weight loss drugs, particularly Mounjaro (tirzepatide) which was approved for type two diabetes in 2022 and later for weight loss under the brand name Zepbound in 2023. The company reported revenue of USD 34.1 billion in 2023, an increase of 20% from the previous year. Lilly expects 2024 revenue to be between USD 40.4 billion and USD 41.6 billion, driven largely by its new products.

Eli Lilly continues to expand its manufacturing capacity to meet growing demand for its incretin medications. The company is investing billions in new production facilities in the US and internationally. Lilly is also advancing its pipeline in areas like Alzheimer's disease, obesity, and immunology. With its strong portfolio of current and potential future blockbuster drugs, Eli Lilly is well-positioned for continued growth in the coming years.